New RSV vaccine for older adults can result in individual and societal cost savings, benefits

Published on September 6, 2024

Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.

Continue reading on website
Other news

New study provides insight to why COVID vaccines hit some harder than others

September 4, 2024
Researchers published a paper highlighting factors that may explain why some people perceived more side effects than others including stress, exercise, and use of hormonal birth control.

Global experts help nanomedicines deliver on healthcare promise

September 6, 2024
New findings from a global team of expert scientists in academia and industry has generated new research quality standards that will help slash costs and reduce the time it takes to develop advanced nanomedicine treatments and make them available for patients.